AMGN / Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

The Dow Jones Industrial Average of blue chip stocks is trading higher for the week, but is still in correction territory, having posted losses in eac more_horizontal

Amgen AMGN, -2.85% has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases. more_horizontal

The U.S. Food and Drug Administration on Tuesday approved Amgen's biosimilar version of Johnson & Johnson's blockbuster psoriasis treatment Stelara fo more_horizontal

Amgen (AMGN) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acqu more_horizontal

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guid more_horizontal

Amgen (AMGN) came out with quarterly earnings of $4.96 per share, beating the Zacks Consensus Estimate of $4.65 per share. This compares to earnings o more_horizontal

In contrast to market expectations, shares of Amgen, Inc. (NASDAQ:AMGN) remained flat even as the biotechnology giant exceeded third-quarter earnings more_horizontal

Amgen Inc.'s stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again r more_horizontal